DOLASTATIN 15 DERIVATIVES
    121.
    发明专利

    公开(公告)号:HU0103560A2

    公开(公告)日:2002-02-28

    申请号:HU0103560

    申请日:1999-06-23

    Applicant: BASF AG

    Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula IA-B-D-E-F-G(I)and acid salts thereof, wherein A, D, and E are alpha -amino acid residues, B is an alpha -amino acid residue or an alpha -hydroxy acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a beta -hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sulfoxide or an alkylene sulfone. Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier. An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

    Dolastatin 15 derivatives
    125.
    发明专利

    公开(公告)号:CZ2000176A3

    公开(公告)日:2001-06-13

    申请号:CZ2000176

    申请日:1998-07-07

    Applicant: BASF AG

    Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L  (I), and acid salts thereof, wherein A, B, D, E, F, G and K are α-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a &bgr;-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

    129.
    发明专利
    未知

    公开(公告)号:NO20010046D0

    公开(公告)日:2001-01-04

    申请号:NO20010046

    申请日:2001-01-04

    Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula IA-B-D-E-F-G(I)and acid salts thereof, wherein A, D, and E are alpha -amino acid residues, B is an alpha -amino acid residue or an alpha -hydroxy acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a beta -hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sulfoxide or an alkylene sulfone. Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier. An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

    DOLASTATINE 15 DERIVATIVES
    130.
    发明专利

    公开(公告)号:BG104089A

    公开(公告)日:2000-12-29

    申请号:BG10408900

    申请日:2000-01-17

    Applicant: BASF AG

    Abstract: The invention relates to inhibitors of the cellular growth and to their adjunctive to acid salts which are peptides with the formula A - B - D - E - F - (G)r - (K)s - L (I) where A, B, D, E, F, G. and K are -aminoacid residues and s and r are, individually, 0 or 1. L is univalent radical, such as aminogroup, N-substituted aminogroup, beta-hydroxyaminogroup, beta-hydroxyaminogroup, hydrasidogroup, alkoxygroup, thioalkoxygroup, aminooxygroup or oximatogroup. The invention also relates to a method for the treatment of cancer in mammals, including humans which includes the administration of an effective quantity of the above compound in a pharmaceutically acceptable composition. 6 claims

Patent Agency Ranking